Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes

A randomized trial involving patients with acute coronary syndromes showed that prasugrel was superior to ticagrelor with regard to the incidence of death, myocardial infarction, or stroke within 1 year, with no increased risk of bleeding.

Uložené v:
Podrobná bibliografia
Vydané v:The New England journal of medicine Ročník 381; číslo 16; s. 1524 - 1534
Hlavní autori: Schüpke, Stefanie, Neumann, Franz-Josef, Menichelli, Maurizio, Mayer, Katharina, Bernlochner, Isabell, Wöhrle, Jochen, Richardt, Gert, Liebetrau, Christoph, Witzenbichler, Bernhard, Antoniucci, David, Akin, Ibrahim, Bott-Flügel, Lorenz, Fischer, Marcus, Landmesser, Ulf, Katus, Hugo A, Sibbing, Dirk, Seyfarth, Melchior, Janisch, Marion, Boncompagni, Duino, Hilz, Raphaela, Rottbauer, Wolfgang, Okrojek, Rainer, Möllmann, Helge, Hochholzer, Willibald, Migliorini, Angela, Cassese, Salvatore, Mollo, Pasquale, Xhepa, Erion, Kufner, Sebastian, Strehle, Axel, Leggewie, Stefan, Allali, Abdelhakim, Ndrepepa, Gjin, Schühlen, Helmut, Angiolillo, Dominick J, Hamm, Christian W, Hapfelmeier, Alexander, Tölg, Ralph, Trenk, Dietmar, Schunkert, Heribert, Laugwitz, Karl-Ludwig, Kastrati, Adnan
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States Massachusetts Medical Society 17.10.2019
Predmet:
Acute Coronary Syndrome - drug therapy
Acute Coronary Syndrome - mortality
Acute Coronary Syndrome - therapy
Acute coronary syndromes
Aged
Bleeding
Cerebral infarction
Clinical trials
Coronary Thrombosis - epidemiology
Death
Drug dosages
Female
Heart attacks
Hemorrhage - chemically induced
Humans
Implants
Incidence
Kaplan-Meier Estimate
Male
Medical imaging
Middle Aged
Myocardial infarction
Myocardial Infarction - epidemiology
Myocardial Infarction - prevention & control
Percutaneous Coronary Intervention
Platelet Aggregation Inhibitors - adverse effects
Platelet Aggregation Inhibitors - therapeutic use
Prasugrel Hydrochloride - adverse effects
Prasugrel Hydrochloride - therapeutic use
Purinergic P2Y Receptor Antagonists - adverse effects
Purinergic P2Y Receptor Antagonists - therapeutic use
Stents
Stroke - epidemiology
Stroke - prevention & control
Thrombosis
Ticagrelor - adverse effects
Ticagrelor - therapeutic use
Germany
ISSN:0028-4793, 1533-4406, 1533-4406
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:A randomized trial involving patients with acute coronary syndromes showed that prasugrel was superior to ticagrelor with regard to the incidence of death, myocardial infarction, or stroke within 1 year, with no increased risk of bleeding.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa1908973